Combinatorx and Bio*One Capital Establish Combinatorx Singapore for Infectious Disease Product Discovery and Development

Sir David Lane to join the Board of Directors of CombinatoRx Singapore

23-Jan-2006

CombinatoRx, Incorporated and Bio*One Capital of Singapore announced the establishment of CombinatoRx Singapore Pte Ltd. CombinatoRx Singapore and Bio*One also announced that Sir David Lane has joined the CombinatoRx Singapore Board of Directors. CombinatoRx Singapore, will apply CombinatoRx's combination high throughput screening (cHTS) technology to discover and potentially develop novel product candidates to treat infectious diseases, with an initial focus on hepatitis C and Hepatitis B.

As a drug development company, CombinatoRx Singapore will focus on developing a range of preclinical and clinical development capabilities. Located at the Biopolis in Singapore, CombinatoRx Singapore has plans to employ approximately twenty full-time researchers and is expected to commit US$20 million to the development of novel drug candidates for infectious diseases.

In addition, CombinatoRx Singapore and Bio*One Capital announced that Sir David Lane will join the Board of Directors of CombinatoRx Singapore. "We are proud to have attracted an individual of such high caliber to CombinatoRx Singapore's Board of Directors," said Alexis Borisy, President and CEO of CombinatoRx. "His extensive research and industry experience, and leadership in molecular and cell biology research will be extremely valuable as CombinatoRx Singapore works towards advancing the discovery, development and commercialization of its product candidates in Singapore."

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances